AI Article Synopsis

  • Researchers are exploring liver sinusoidal endothelial cells (LSECs) and their progenitor cells (LPCs) from human pluripotent stem cells (PSCs) as potential treatments for hemophilia A, a condition caused by insufficient coagulation factor VIII (FVIII) production.* -
  • The study aimed to enhance the process of mesoderm differentiation to efficiently produce LSEC-like cells from human induced pluripotent stem cells (iPSCs), observing a successful differentiation rate of approximately 65% for LPCs and 54% for LSEC-like cells.* -
  • Optimizing specific factors like CHIR99021 and bone morphogenetic protein 4 led to significant FVIII protein secretion from L

Article Abstract

Liver sinusoidal endothelial cells (LSECs) and LSEC progenitor cells (LPCs) derived from human pluripotent stem cells (PSCs) are expected as valuable cell sources for the development of cell therapy for hemophilia A, a congenital deficiency of coagulation factor VIII (FVIII), as LSECs are responsible for FVIII production. However, there is room for improvement in the efficiency of LSEC and LPC differentiation from human PSCs. In this study, we sought to optimize the method of mesoderm differentiation induction, the initial step of LSEC differentiation from human PSCs, to efficiently induce LSEC-like cells capable of secreting FVIII from human induced pluripotent stem cells (iPSCs). Following optimization of the concentration and stimulation period of CHIR99021 (glycogen synthase kinase 3β inhibitor), bone morphogenetic protein 4, fibroblast growth factor 2, and Activin A in the mesoderm induction step, approximately 65% and 54% of cells differentiated into LPCs and LSEC-like cells, respectively. Furthermore, we observed substantial FVIII protein secretion from LSEC-like cells . In conclusion, we established an efficient method for obtaining LPCs and functional LSEC-like cells from human iPSCs .

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11570519PMC
http://dx.doi.org/10.1016/j.omtm.2024.101355DOI Listing

Publication Analysis

Top Keywords

lsec-like cells
16
pluripotent stem
12
stem cells
12
cells
11
liver sinusoidal
8
coagulation factor
8
factor viii
8
human induced
8
induced pluripotent
8
differentiation human
8

Similar Publications

Article Synopsis
  • Researchers are exploring liver sinusoidal endothelial cells (LSECs) and their progenitor cells (LPCs) from human pluripotent stem cells (PSCs) as potential treatments for hemophilia A, a condition caused by insufficient coagulation factor VIII (FVIII) production.* -
  • The study aimed to enhance the process of mesoderm differentiation to efficiently produce LSEC-like cells from human induced pluripotent stem cells (iPSCs), observing a successful differentiation rate of approximately 65% for LPCs and 54% for LSEC-like cells.* -
  • Optimizing specific factors like CHIR99021 and bone morphogenetic protein 4 led to significant FVIII protein secretion from L
View Article and Find Full Text PDF

A novel efficient strategy to generate liver sinusoidal endothelial cells from human pluripotent stem cells.

Sci Rep

June 2024

Guangdong Provincial Key Laboratory of Large Animal Models for Biomedicine, and South China Institute of Large Animal Models for Biomedicine, School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, Guangdong, China.

Liver sinusoidal endothelial cells (LSECs) are highly specialized endothelial cells (ECs) that play an important role in liver development and regeneration. Additionally, it is involved in various pathological processes, including steatosis, inflammation, fibrosis and hepatocellular carcinoma. However, the rapid dedifferentiation of LSECs after culture greatly limits their use in vitro modeling for biomedical applications.

View Article and Find Full Text PDF

Background & Aims: Liver sinusoidal endothelial cells (LSECs) are important in liver development, regeneration, and pathophysiology, but the differentiation process underlying their tissue-specific phenotype is poorly understood and difficult to study because primary human cells are scarce. The aim of this study was to use human induced pluripotent stem cell (hiPSC)-derived LSEC-like cells to investigate the differentiation process of LSECs.

Methods: hiPSC-derived endothelial cells (iECs) were transplanted into the livers of // mice and assessed over a 12-week period.

View Article and Find Full Text PDF

Introduction: Liver sinusoidal endothelial cells (LSECs) are specialized vascular endothelial cells that play an important role in the maintenance of biological homeostasis. However, the lack of versatile human LSECs has hindered research on LSECs and development of medical technologies for liver diseases including hemophilia A. In this study, we developed a technique to induce LSEC differentiation from human bone marrow-derived mesenchymal stem cells (BM-MSCs).

View Article and Find Full Text PDF

To date, there is no representative in vitro model for liver sinusoidal endothelial cells (LSECs), as primary LSECs dedifferentiate very fast in culture and no combination of cytokines or growth factors can induce an LSEC fate in (pluripotent stem cell (PSC)-derived) endothelial cells (ECs). Furthermore, the transcriptional programmes driving an LSEC fate have not yet been described. Here, we first present a computational workflow (CenTFinder) that can identify transcription factors (TFs) that are crucial for modulating pathways involved in cell lineage specification.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!